活化半胱胺酸蛋白酶蛋白-9抗體
- 發(fā)布日期： 2023-11-20
- 更新日期： 2025-10-10
產(chǎn)品詳請
| 產(chǎn)地 |
上海
|
| 品牌 |
森興研
|
| 保存條件 |
Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
|
| 貨號 |
|
| 用途 |
|
| 應(yīng)用范圍 |
WB=1:500-2000 ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1μg/test ICC=1:100 IF=1:100-500 （石蠟切片需做抗原修復(fù)） not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user.
|
| 抗原來源 |
Rabbit
|
| 保質(zhì)期 |
|
| 抗體名 |
Caspase-9
|
| 是否單克隆 |
否
|
| 克隆性 |
是
|
| 靶點(diǎn) |
|
| 適應(yīng)物種 |
咨詢
|
| 形態(tài) |
Liquid
|
| 宿主 |
咨詢
|
| 標(biāo)記物 |
|
| 包裝規(guī)格 |
100ul
|
| 亞型 |
IgG
|
| 標(biāo)識物 |
|
| 濃度 |
1mg/ml%
|
| 免疫原 |
KLH conjugated synthetic peptide derived from human Caspase-9 subunit p35: 11-120/416
|
| 是否進(jìn)口 |
否
|
研究領(lǐng)域腫瘤 細(xì)胞生物 神經(jīng)生物學(xué) 信號轉(zhuǎn)導(dǎo) 細(xì)胞凋亡
抗體來源Rabbit
克隆類型Polyclonal
交叉反應(yīng)Human, Mouse, Rat, Dog, (predicted: Cow, )
產(chǎn)品應(yīng)用WB=1:500-2000 ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1μg/test ICC=1:100 IF=1:100-500 （石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
理論分子量35/50kDa
細(xì)胞定位細(xì)胞漿
性 狀Liquid
濃 度1mg/ml
免 疫 原KLH conjugated synthetic peptide derived from human Caspase-9 subunit p35: 11-120/416
亞 型IgG
純化方法affinity purified by Protein A
緩 沖 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存條件Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
注意事項(xiàng)This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
PubMedPubMed
產(chǎn)品介紹Caspase 9 (also known as ICE like apoptotic protease 6 (ICE LAP6), apoptotic protease Mch6, and apoptotic protease activating factor 3 (Apaf3)) is a member of the peptidase family C14 that contains a CARD domain. This caspase is active as a heterotetramer and has been reported to have two isoforms. ProCaspase 9 has been reported to be approximately 47 kD. This caspase is present in the cytosol and, upon activation, translocates to the mitochondria. Caspase 9 is involved in the caspase activation cascade responsible for apoptosis execution and cleaves/activates Caspase 3 and Caspase 6. Caspase 9 is inhibited by the dominant negative isoform, BclXL, cIAP1, cIAP2, XIAP, and Livin. This caspase becomes activated when recruited to Apaf1/cytochrome c complex, and following cleavage by Apaf1, granzyme B, Caspase 3, possibly Caspase 8 and Caspase 10 into large p37 and small p10 subunits. Caspase 9 intereacts with BIRC7 and has been shown to cleave PARP and vimentin.
Function:
Involved in the activation cascade of caspases responsible for apoptosis execution. Binding of caspase-9 to Apaf-1 leads to activation of the protease which then cleaves and activates caspase-3. Proteolytically cleaves poly(ADP-ribose) polymerase (PARP).
Isoform 2 lacks activity is an dominant-negative inhibitor of caspase-9.
Subunit:
Heterotetramer that consists of two anti-parallel arranged heterodimers, each one formed by a 35 kDa (p35) and a 10 kDa (p10) subunit. Caspase-9 and APAF1 bind to each other via their respective NH2-terminal CED-3 homologous domains in the presence of cytochrome C and ATP. Interacts (inactive form) with EFHD2. Interacts with HAX1. Interacts with BIRC2/c-IAP1, XIAP/BIRC4, BIRC5/survivin, BIRC6/bruce and BIRC7/livin.
Tissue Specificity:
Ubiquitous, with highest expression in the heart, moderate expression in liver, skeletal muscle, and pancreas. Low levels in all other tissues. Within the heart, specifically expressed in myocytes.
Post-translational modifications:
Cleavages at Asp-315 by granzyme B and at Asp-330 by caspase-3 generate the two active subunits. Caspase-8 and -10 can also be involved in these processing events.
Phosphorylated at Thr-125 by MAPK1/ERK2. Phosphorylation at Thr-125 is sufficient to block caspase-9 processing and subsequent caspase-3 activation.
Similarity:
Belongs to the peptidase C14A family.
Contains 1 CARD domain.
SWISS:
P55211
Gene ID:
842
